Other Publications Referenced in Amarin’s Investor Communications ≪ Back to Publications To search publications using the available search words, please click here: Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction. Boden WE, Baum S, Toth PP, et al. Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction. Future Cardiol. 2020; epub ahead of print. https://www.futuremedicine.com/doi/pdf/10.2217/fca-2020-0106 cardiovascular disease EPA heart disease IPE Targeting hypertriglyceridemia to mitigate cardiovascular risk: a review. Toth PP, Shah PK, Lepor NE. Targeting hypertriglyceridemia to mitigate cardiovascular risk: a review. Am J Prevent Cardiol. 2020; epub ahead of print. https://www.sciencedirect.com/science/article/pii/S2666667720300866 cardiovascular risk EPA IPE REDUCE-IT trial TG
Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction. Boden WE, Baum S, Toth PP, et al. Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction. Future Cardiol. 2020; epub ahead of print. https://www.futuremedicine.com/doi/pdf/10.2217/fca-2020-0106 cardiovascular disease EPA heart disease IPE
Targeting hypertriglyceridemia to mitigate cardiovascular risk: a review. Toth PP, Shah PK, Lepor NE. Targeting hypertriglyceridemia to mitigate cardiovascular risk: a review. Am J Prevent Cardiol. 2020; epub ahead of print. https://www.sciencedirect.com/science/article/pii/S2666667720300866 cardiovascular risk EPA IPE REDUCE-IT trial TG